How Sepsis Affects Parkinson's Disease Symptoms
Sepsis can significantly worsen both motor and non-motor symptoms in Parkinson's disease patients, primarily through infection-induced inflammation and medication disruptions during acute illness, with infections being a major risk factor for motor deterioration during hospitalization.
Mechanisms of Symptom Exacerbation
Sepsis impacts Parkinson's disease through multiple pathways:
Inflammatory cascade: Sepsis triggers systemic inflammation with elevated IL-6 and IL-17A, cytokines that correlate directly with motor symptom severity and non-motor symptom burden in PD patients 1. This inflammatory response can temporarily unmask or worsen underlying parkinsonian features.
Medication disruptions: During septic episodes requiring hospitalization, medication errors occur in approximately 39% of PD patients, representing the most significant risk factor for motor function deterioration 2. The nil per os (NPO) state during acute sepsis prevents oral dopaminergic medication administration, leading to rapid symptom worsening.
Altered mental status: Sepsis-induced delirium and confusion (occurring in 24% of hospitalized PD patients) can mask or complicate the assessment of parkinsonian symptoms 2.
Clinical Impact During Acute Sepsis
Motor symptoms: Approximately 28% of hospitalized PD patients experience significant motor deterioration, defined as a mean increase of more than 5 points on the UPDRS-III scale at discharge 2. This worsening is directly attributable to:
- Infection itself (15% of complications during hospitalization)
- Inability to maintain regular dopaminergic medication schedules
- Systemic inflammatory effects on dopaminergic pathways
Non-motor symptoms: Sepsis exacerbates cognitive dysfunction, autonomic instability, and psychiatric symptoms through inflammatory mediators and metabolic derangements associated with severe infection 1.
Critical Management Considerations
During NPO State
When PD patients with sepsis cannot take oral medications, use alternative formulations:
- Apomorphine subcutaneous injections
- Rotigotine transdermal patches (can remain in place)
- Inhalational levodopa when available
These alternatives prevent the catastrophic motor deterioration that occurs when dopaminergic therapy is abruptly discontinued 3.
Medication Reconciliation
Implement PD-specific protocols during sepsis admission to prevent the 39% medication error rate. Staff education on the critical timing requirements of antiparkinsonian medications is essential 2.
Patient Autonomy
Allow PD patients to self-administer their own parkinsonian medications whenever medically feasible—in one study, 24% of patients maintained control of their medications and none of these patients deteriorated 2.
Long-Term Considerations
Bidirectional relationship: While acute sepsis worsens PD symptoms, there is preliminary evidence that CNS infections (but not systemic sepsis) may increase future PD risk when occurring years before diagnosis 4. However, this association is primarily relevant for multiple CNS infections occurring at least 5 years prior (OR = 3.3), not for systemic sepsis.
Post-sepsis vulnerability: PD patients demonstrate increased susceptibility to subsequent infections after the index date, with hazard ratios of 1.8 for CNS infections and 2.2 for sepsis compared to controls 4.
Common Pitfalls to Avoid
- Never abruptly discontinue dopaminergic medications during sepsis management—this can precipitate akinetic crisis
- Do not assume confusion is solely from sepsis—it may represent worsening PD symptoms from medication disruption
- Avoid dopamine antagonists (metoclopramide, prochlorperazine) for nausea in septic PD patients, as these worsen motor symptoms
- Do not delay antibiotic therapy to accommodate PD medication timing—use alternative formulations instead 5, 6
The priority during sepsis management in PD patients is maintaining hemodynamic stability and treating infection per standard sepsis guidelines 6, while simultaneously preventing iatrogenic worsening of parkinsonian symptoms through medication continuity and infection prevention strategies 2, 3.